DICOT.ST

Sinker

Dicot Pharma AB · Healthcare · Sweden · $75M cap · $157K/day traded

SEK 0.208 -1.0% · close 18 Nov · scored 19 Nov

Score down 1.2 since 18 Nov: Momentum down 3 after a 1% price fall.

Sinker: Weak business, rich price and weak momentum. Nothing here to keep it afloat.

9
Score
Get score and insider alerts
Quality
25
Value
27
Momentum
28

As of 19 Nov 2026, the MoatMap Score for Dicot Pharma AB (DICOT.ST) is 9/100, ranked against 25,000+ stocks in 38 markets (Quality 25, Value 27, Momentum 28, each scored against its sector).

Does the score work? Each tenth of the ranking, tracked monthly. See the record →

P/E (TTM)
—
peers 32.6x
ROE
-46.9%
peers 5.7%
D/E
0.0x
peers 0.2x
Dividend %
—
trailing yield

ABOUT DICOT PHARMA AB

Read

Dicot Pharma AB is a clinical-stage pharmaceutical company developing a novel, long-acting drug candidate, LIB-01, for the treatment of erectile dysfunction and other sexual dysfunctions. Unlike existing short-acting PDE5 inhibitors, LIB-01 aims to provide a therapeutic effect lasting for several days, significantly improving patient spontaneity and quality of life. The company is protected by a robust global patent portfolio and targets a massive, established global market seeking next-generation treatment options.

FINANCIAL SUMMARY (SEK)

Year2022202320242025CAGRTTM
Income and shares
Revenue——————
Net marginn/mn/mn/mn/m——
EPS (SEK)-0.02-0.06-0.04-0.04—-0.04
Share count3.5B3.5B2.0B2.3B-13.4%—
Balance sheet
Debt——————
Equity5.4M44.4M111.7M73.4M139.2%—
Debt/equity——————
Cash flow
Op. cash flow-29.7M-45.2M-58.9M-85.9M—-79.0M
Cash flow marginn/mn/mn/mn/m——
Investing CF——————
Financing CF8.8M83.2M124.9M41.6M——

Cash on hand equals about 2.9 years of the operating cash used in the last twelve months. Spending on equipment or exploration and any new funding are not counted.

PRICE (1Y) · SEK-18.0%
0.210.220.230.240.258 Oct29 Oct18 Nov
SMA 50SMA 200

Price checkFinding a floorExperimental

No new 52-week low for 16 weeks, 19% above that low, but not back above a rising 50-day average.

SwingsVery bumpy

Swung more than 83% of stocks we rank over the past year (volatility 72% a year).

How this is worked out

The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.

  • Still falling: It set a new 52-week low in the last two weeks, after a deep fall.
  • Finding a floor (this stock): It fell hard, but has set no new low for more than two weeks.
  • Turning up: It has climbed off its low and is back above a rising 50-day average.
  • In an uptrend: It is near its 52-week high and above its 200-day average.
  • No clear trend: None of the above: no recent deep fall and no steady climb.
  • No read yet: Not enough price history yet: it needs a year of trading.

In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.

The exact rules

Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.

In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.

What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.

What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.

Calm is not safe: a calm stock can still slide steadily.

Rules fixed before any data was fetched. Describes the chart, not a recommendation.

Close
SEK 0.208
RSI (14)
41.3
52-Week Range-61.5% from high
Low SEK 0.175High SEK 0.54

SCORE BREAKDOWN

Quality
25
ROIC
-109.4%5.9
ROE
-46.9%18.5
GP/Assets
0.0%9.2
Op. Margin
0.0%38.9
FCF/Assets
-57.1%6.3
Piotroski
00.2
Int. Cover
-50.0x5.8
D/E Ratio
0.00x98.1
Current Ratio
27.38x97.8
Value
27
P/E (TTM)
—N/A
EV/EBITDA
—N/A
P/FCF
—N/A
P/B
3.3x37.9
P/S
—N/A
Div Yield
—N/A
Momentum
28
52W High %
39%19.4
RS 6M
-12%38.1
SMA 50/200
0.87x29.3
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$75M
P/E (Forward)
—
Gross Margin
—

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DICOT.ST are excluded.

TickerCompanyMkt CapScore
DICOT.STDicot Pharma AB(you)$75M9
CRNO-B.STCereno Scientific AB (publ)$97M6
CINPHA.STCinclus Pharma Holding AB (publ)$55M7
ORX.STOrexo AB (publ)$55M11
EQL.STEQL Pharma AB (publ)$59M20
MOB.STMoberg Pharma AB (publ)$52M31
NANEXA.STNanexa AB (publ)$205M69
SYNACT.STSynAct Pharma AB$97M10
MVIR.STMedivir AB (publ)$94M6
ONCO.STOncopeptides AB (publ)$65M14

Peer medians: ROE 5.7% · P/E 32.6x · Gross margin 68.3%

Company Deep Dive

A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.

Request Deep Dive(50 Feathers)

Dicot Pharma AB (DICOT.ST): Stock Score Summary

Dicot Pharma AB (DICOT.ST) has a MoatMap Score of 9/100 based on Quality (25/100), Value (27/100), and Momentum (28/100) factor scores.

Dicot Pharma AB is a clinical-stage pharmaceutical company developing a novel, long-acting drug candidate, LIB-01, for the treatment of erectile dysfunction and other sexual dysfunctions. Unlike existing short-acting PDE5 inhibitors, LIB-01 aims to provide a therapeutic effect lasting for several days, significantly improving patient spontaneity and quality of life. The company is protected by a robust global patent portfolio and targets a massive, established global market seeking next-generation treatment options.

Director dealings

From 19 Nov 2025 to 19 Nov 2026, MoatMap's records hold no sales and 1 purchase of Dicot Pharma AB (DICOT.ST) shares by its directors. The largest: Håkan Wickholm bought 29,000 shares at SEK 0.37 on 3 Dec 2025 (about SEK 11K).

DICOT.ST insider filings, last 180 days

Key Financial Metrics

PriceSEK 0.208
Market Cap$75M
Price/Book3.30
Return on Equity-46.9%
Return on Invested Capital-109.4%
Debt/Equity0.00x
Operating Margin0.0%
Free Cash Flow$-5M

Dicot Pharma AB operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (Sweden).

Frequently Asked Questions

What is Dicot Pharma AB’s (DICOT.ST) MoatMap Score?
The MoatMap Score for Dicot Pharma AB (DICOT.ST) is 9/100. It is a composite of Quality (25), Value (27), and Momentum (28), each scored against its sector. The composite is then ranked across MoatMap’s universe of 25,000+ stocks.
Does Dicot Pharma AB have an economic moat?
Dicot Pharma AB (DICOT.ST) has a Quality factor score of 25/100. Quality blends several measures of profitability and financial strength, led by gross profit to assets, return on invested capital and free cash flow to assets. A high score describes the financial record a durable advantage tends to leave; it does not prove a moat.
What sector is Dicot Pharma AB in?
Dicot Pharma AB (DICOT.ST) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (Sweden).